397 related articles for article (PubMed ID: 9141518)
1. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
2. Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
Schwartz JI; Van Hecken A; De Schepper PJ; De Lepeleire I; Lasseter KC; Shamblen EC; Winchell GA; Constanzer ML; Chavez CM; Wang DZ; Ebel DL; Justice SJ; Gertz BJ
J Clin Endocrinol Metab; 1996 Aug; 81(8):2942-7. PubMed ID: 8768856
[TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
4. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.
Amory JK; Wang C; Swerdloff RS; Anawalt BD; Matsumoto AM; Bremner WJ; Walker SE; Haberer LJ; Clark RV
J Clin Endocrinol Metab; 2007 May; 92(5):1659-65. PubMed ID: 17299062
[TBL] [Abstract][Full Text] [Related]
5. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
Gormley GJ; Stoner E; Rittmaster RS; Gregg H; Thompson DL; Lasseter KC; Vlasses PH; Stein EA
J Clin Endocrinol Metab; 1990 Apr; 70(4):1136-41. PubMed ID: 2156887
[TBL] [Abstract][Full Text] [Related]
6. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
[TBL] [Abstract][Full Text] [Related]
7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
8. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
9. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO; Hermann D; Hammarlund-Udenaes M; Karlsson MO
Clin Pharmacol Ther; 1998 Dec; 64(6):636-47. PubMed ID: 9871428
[TBL] [Abstract][Full Text] [Related]
10. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.
Dallob AL; Sadick NS; Unger W; Lipert S; Geissler LA; Gregoire SL; Nguyen HH; Moore EC; Tanaka WK
J Clin Endocrinol Metab; 1994 Sep; 79(3):703-6. PubMed ID: 8077349
[TBL] [Abstract][Full Text] [Related]
11. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
[TBL] [Abstract][Full Text] [Related]
12. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.
Vermeulen A; Giagulli VA; De Schepper P; Buntinx A; Stoner E
Prostate; 1989; 14(1):45-53. PubMed ID: 2538808
[TBL] [Abstract][Full Text] [Related]
13. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
[TBL] [Abstract][Full Text] [Related]
14. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor.
De Schepper PJ; Imperato-McGinley J; Van Hecken A; De Lepeleire I; Buntinx A; Carlin J; Gressi MH; Stoner E
Steroids; 1991 Sep; 56(9):469-71. PubMed ID: 1666698
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
16. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
17. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
18. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
19. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.
Caserini M; Radicioni M; Leuratti C; Terragni E; Iorizzo M; Palmieri R
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):19-27. PubMed ID: 26636418
[TBL] [Abstract][Full Text] [Related]
20. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
